MRSA infections detected during the ICU stay.

<p><b>NOTE</b>. MRSA, methicillin-resistant <i>Staphylococcus aureus</i>.</p

Risk factors for MRSA colonization in 282 patients.

<p><b>NOTE</b>. MRSA, methicillin-resistant <i>Staphylococcus aureus</i>.</p

Univariate and Multivariate analyses for risk factors associated with 30-day mortality in patients with MRSA bacteremia.

<p><b>NOTE</b>. HR, hazard ratio; CI, confidence interval; APACHE, acute physiology and chronic health evaluation; SCC<i>mec</i> IV/IVa MRSA, MRSA possessing SCC<i>mec</i> type IV or IVa; hetero-VISA, hetero-vancomycin-intermediate <i>S. aureus</i>; MIC, minimum inhibitory concentration.</p>a<p>Continuous variables are expressed as means (±SD).</p>b<p>Statistically significant (<i>P</i>≤0.05).</p

Sensitivity of MRSA surveillance culture for each anatomical site.

<p><b>A.</b> Sensitivity of MRSA surveillance culture by collection time. White bars: sensitivity at the time of admission; black bars: sensitivity of cultures collected during the ICU stay. <b>B.</b> Sensitivity of MRSA surveillance culture according to intubation. White bars: intubated patients; black bars: non-intubated patients.</p

Sensitivity, specificity, and predictive value of MRSA surveillance culture by anatomical site.

<p>NOTE. MRSA, methicillin-resistant <i>Staphylococcus aureus</i>.</p><p>a; Nasal + trachea/throat + rectum + skin.</p

MRSA surveillance cultures as a predictor of MRSA infection by anatomical site.

<p><b>A.</b> ROC curve of MRSA surveillance as a predictor of overall MRSA infection. AUC: nasal cultures, 0.648 (95% CI, 0.590-0.704); trachea/throat cultures, 0.675 (95% CI, 0.617-0.729); all 4 sites, 0.706 (95% CI, 0.649-0.759) (<i>P</i>>0.05). <b>B.</b> ROC curve of MRSA surveillance as a predictor of MRSA pneumonia. AUC: nasal cultures, 0.649 (95% CI, 0.590-0.705); trachea/throat cultures, 0.791 (95% CI, 0.739-0.837); all 4 sites, 0.748 (95% CI, 0.693-0.797).</p

Adjusted 30-day crude and 30-day <i>S. aureus</i>-related mortalities in patients with SCC<i>mec</i> IV/IVa MRSAB or SCC<i>mec</i> I–III MRSAB.

<p>A. Adjusted 30-day mortalities in patients with SCC<i>mec</i> IV/IVa MRSAB or SCC<i>mec</i> I–III MRSAB by multivariate Cox-regression survival analysis. B. Adjusted 30-day <i>S. aureus</i>-related mortalities in patients with SCC<i>mec</i> IV/IVa MRSAB or SCC<i>mec</i> I–III MRSAB by multivariate Cox-regression survival analysis. NOTE. SCC<i>mec</i> IV/IVa MRSAB, bacteremia caused by MRSA possessing SCC<i>mec</i> type IV or IVa; SCC<i>mec</i> type I–III MRSAB, bacteremia caused by MRSA possessing SCC<i>mec</i> types I–III.</p

Clinical features of 307 patients with SCC<i>mec</i> IV/IVa MRSAB or SCC<i>mec</i> I–III MRSAB.

<p><b>NOTE</b>. SCC<i>mec</i> IV/IVa MRSAB, bacteremia caused by MRSA possessing SCC<i>mec</i> type IV or IVa; SCC<i>mec</i> I–III MRSAB, bacteremia caused by MRSA possessing SCC<i>mec</i> types I–III; APACHE, acute physiology and chronic health evaluation.</p>a<p>Continuous variables are expressed as means (±SD).</p>b<p>Statistically significant (<i>P</i>≤0.05).</p>c<p>Expressed as number of deaths/number of patients followed up (%).</p

Kaplan-Meier survival curves of propensity-score-matched patients treated with a TGC plus doxycycline or TGC plus ciprofloxacin.

There was no significant difference in survival between the two groups by the log-rank test (P = 0.46).</p

Clinical features and outcomes of 310 patients with viral or non-viral community-acquired pneumonia.

<p>Continuous variables were expressed as means ± SDs^a or medians (IQRs)^b and were compared by the Student's t test^a or Mann-Whitney U test^b.</p><p>CURB-65: Confusion-Urea-Respiratory-Blood pressure-65 score, PSI: Pneumonia severity index, ICU: Intensive care unit.</p><p>Clinical features and outcomes of 310 patients with viral or non-viral community-acquired pneumonia.</p